The road has been long, winding, and potholed for USG Corp. (USG), a leading manufacturer and distributor of residential and commercial materials (best known for its ubiquitous Sheetrock wall-siding brand).

In July 2001, the company declared Chapter 11 bankruptcy to manage intractable asbestos litigation costs.

In the prior eight years, USG had been named in more than 250,000 asbestos-related personal injury claims and had paid more than $450 million (before insurance) to resolve asbestos-related litigation.

Five years later, in Feb. 2006, USG announced a reorganization to emerge from Chapter 11. Under the court-approved plan, all present and future asbestos personal injury claims against the company have been permanently channeled to an independent personal injury trust that is responsible for administering and paying claims.

As part of the plan, USG's bank lenders, bondholders, and trade suppliers would be paid in full with interest. Stockholders would retain ownership of the company. To fund the trust, USG will use accumulated cash, new long-term debt, and a $1.8 billion rights offering.

In the recently completed offering, existing USG stockowners received rights to buy new USG stock at $40 per share. The offering was backstopped by Berkshire Hathaway Inc. (BRK.A), meaning Berkshire Hathaway was responsible for purchasing any unbought shares, which it did to the tune of 6.97 million shares (raising its stake to 17.3% of shares outstanding).

Today, litigation is behind USG, and its stock trades around $46, a 44% discount to its rights-adjusted high of $80 set back in April.

What happened? Now that litigation woes are in the rearview mirror, investors are looking ahead to economic reality: USG's business is cyclical. Its fortunes are tethered to the level of new commercial and home construction (which have been terrible), re-sales and home improvements (which have slowed), and raw-material costs (which have ballooned).

However, USG is demonstrating some chutzpah in this tough environment. It recently reported second-quarter profits of $176 million, or $1.97 a share, compared with $110 million, or $1.24 a share, in 2005. What's more, sales rose 22 percent to $1.57 billion, a new record.

Nevertheless, consensus estimates call for EPS to tumble 46 percent in fiscal year 2007; hence, the similar percentage drop in USG's stock.

Could the price drop be too much? I think so. Focusing on near-term problems obscures long-term investability. And long term, USG looks solid, at least based on a rudimentary net-present-value (NPV) calculation (any Warren Buffett investment begs for NPV).

I'm a conservative investor, so my beginning NPV calculation includes 2006 EPS of $7, a 35 percent annual two-year EPS contraction (I think the next two years could be rough), 4 percent annual EPS growth thereafter, and a 10% discount rate (Why 10%? It's a nice round number, it approaches the long-run return of the S&P 500, and it's a number John D. Rockefeller used in his business dealings).

Given the aforementioned inputs, I calculate a net present value of $48 per share, which admittedly, leaves little margin for error. But if I change the variables slightly to an equally reasonable 30% annual EPS contraction over two years and 5% EPS growth thereafter (to more liberally account for the Buffett factor, eventual industry improvement, management know how, and lack of litigation), I calculate a NPV of $67 per share.

Of course, I could plug in any inputs to make the NPV fit my objective, but USG has precedence on its side. Many companies – Halliburton (HAL), Altria (MO), American Express (AXP), and US Smokeless Tobacco (UST), for example – have proven that once the Damocles Sword of litigation is removed, exemplary shareholder gains follow.

Related Articles
  1. Mutual Funds & ETFs

    ETF Analysis: ProShares Ultra Nasdaq Biotechnology

    Find out information about the ProShares Ultra Nasdaq Biotechnology exchange-traded fund, and learn detailed analysis of its characteristics and suitability.
  2. Mutual Funds & ETFs

    ETF Analysis: Direxion Daily S&P Biotech Bull 3X

    Learn more about the Direxion Daily S&P Biotech Bull 3x exchange-traded fund, a new triple-leveraged ETF tracking biotechnology equities.
  3. Mutual Funds & ETFs

    ETF Analysis: First Trust Health Care AlphaDEX

    Learn more about the First Trust Health Care AlphaDEX exchange-traded fund, an indexed fund that uses an advanced stock selection methodology.
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares FTSE RAFI Emerging Mkts

    Learn more about the PowerShares FTSE RAFI Emerging Markets ETF, a fundamentally weighted fund that tracks emerging market equities.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Cali AMT-Free Muni Bond

    Learn more about the iShares California AMT-Free Municipal Bond exchange-traded fund, a popular tax-advantaged ETF that dominates its category.
  6. Mutual Funds & ETFs

    ETF Analysis: SPDR S&P Emerging Markets Dividend

    Learn more about the SDPR S&P Emerging Markets Dividend Fund, a yield-focused exchange-traded fund tracking global emerging economies.
  7. Mutual Funds & ETFs

    ETF Analysis: First Trust Dow Jones Global Sel Div

    Find out about the First Trust Dow Jones Global Select Dividend Index Fund, and learn detailed information about characteristics and suitability of the fund.
  8. Mutual Funds & ETFs

    ETF Analysis: U.S 12 Month Natural Gas

    Learn about the United States 12 Month Natural Gas Fund, an exchange-traded fund that invests in 12-month futures contracts for natural gas.
  9. Mutual Funds & ETFs

    ETF Analysis: iShares Floating Rate Bond

    Explore detailed analysis and information of the iShares Floating Rate Bond ETF, and learn how to use this ETF as a defense against rising interest rates.
  10. Mutual Funds & ETFs

    ETF Analysis: ProShares UltraPro Short S&P500

    Find out information about the ProShares UltraPro Short S&P 500 exchange-traded fund, and learn detailed analysis of its characteristics and suitability.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Exchange-Traded Fund (ETF)

    A security that tracks an index, a commodity or a basket of assets ...
  3. Hunting Elephants

    The practice of targeting large companies or customers.
  4. Exchange-Traded Mutual Funds (ETMF)

    Investopedia explains the definition of exchange-traded mutual ...
  5. Warren Buffett

    Known as "the Oracle of Omaha", Buffett is Chairman of Berkshire ...
  6. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
RELATED FAQS
  1. Can mutual funds invest in IPOs?

    Mutual funds can invest in initial public offerings (IPOS). However, most mutual funds have bylaws that prevent them from ... Read Full Answer >>
  2. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. What does a high turnover ratio signify for an investment fund?

    If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>
  6. Does index trading increase market vulnerability?

    The rise of index trading may increase the overall vulnerability of the stock market due to increased correlations between ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!